Page 104 - Read Online

Alqahtani et al. Hepatoma Res 2020;6:58 I http://dx.doi.org/10.20517/2394-5079.2020.49 Page 13 of 18

REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al; Global Burden of Disease Liver Cancer Collaboration. The Burden
of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the
Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
3. Caviglia GP, Rizzetto M. Treatment of hepatitis D: an unmet medical need. Clin Microbiol Infect 2020;26:824-7.
4. Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, et al. A territorywide prevalence study on blood-borne and enteric viral hepatitis in
Hong Kong. J Infect Dis 2019;219:1924-33.
5. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-
analysis of observational studies. J Hepatol 2020: doi: 10.1016/j.jhep.2020.02.030.
6. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from
the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 2019;70:674-83.
7. Maticic M, Mondelli MU. Elimination of viral hepatitis: where do we stand in the year 2020? Clin Microbiol Infect 2020;26:816-7.
8. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol 2016;64:S41-8.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
10. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic
review and meta-analysis. Liver Int 2016;36:1239-51.
11. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014;384:2053-63.
12. Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur
J Cancer Prev 2018;27:205-12.
13. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in
causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-12.
14. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in
causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
15. Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int
2016;10:574-93.
16. Yang H, Yuen M, Chan HL, Han K, Chen P, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B):
development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
17. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and
management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
18. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B
carriers. J Clin Oncol 2010;28:1660-5.
19. Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol
2015;63:722-32.
20. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, et al; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and
the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
21. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
2004;130:417-22.
22. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for
hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-8.
23. Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B virus infection and alcohol consumption. World J Gastroenterol
2017;23:2651-9.
24. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, et al. Interaction between cigarette smoking and hepatitis B and C virus infection on
the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1261-8.
25. Liu X, Baecker A, Wu M, Zhou JY, Yang J, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver
cancer in a Chinese population. Int J Cancer 2018;142:1560-7.
26. Kim K, Choi S, Park SM. Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus
infection: a Korean population-based cohort study. JAMA Oncol 2018;4:737-9.
27. Tan Y, Wei S, Zhang W, Yang J, Yang J, et al. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with
chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res 2019;11:705-13.
28. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study.
Hepatology 2017;65:828-35.
29. Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results
of a large case-control study. J Viral Hepat 2018;25:97-104.
30. Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, et al. Association between hepatic steatosis, measured by controlled attenuation
parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol 2018;16:575-83.e2.
31. Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in
patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther
2014;39:883-93.